Gilead says coronavirus drug remdesivir can reduce risk of death, but analysts need more proof

Shares of Gilead Sciences Inc. gained 2.0% on Friday after the drugmaker shared potentially promising data about remdesivir that indicates the experimental COVID-19 drug may reduce deaths, though it noted the findings need to be confirmed.